RxDoctor Payments Data

John Sim, MD

Internal Medicine · Santa Barbara, CANPI 1497857510

Payments from drug & device makers

$1,167in general payments, 2019–2025

Across 70 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$260
  • Boehringer Ingelheim$187
  • Calliditas Therapeutics US Inc.$123
  • Amgen$114
  • Johnson & Johnson$104
  • Amarin Pharma, Inc.$77
  • plus $302 from 10 others

What the payments were for

  • Food & beverage$1,167100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,167 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$120,876
Medicare patients
424
Services billed
1,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$79,046
OzempicSemaglutide31$34,500
MyrbetriqMirabegron16$21,520
JardianceEmpagliflozin12$19,406
XareltoRivaroxaban13$18,447
TrulicityDulaglutide15$12,659
Advair HfaFluticasone Propion/Salmeterol27$8,799
DiovanValsartan12$8,099
LinzessLinaclotide13$6,475
Atorvastatin Calcium673$5,883
PaxlovidNirmatrelvir/Ritonavir16$4,288
Levothyroxine Sodium295$3,965
Valsartan114$3,230
Amlodipine Besylate375$3,032
Losartan Potassium224$2,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$260$83,334102 claims
Boehringer IngelheimJardiance$187$19,40612 claims
Johnson & JohnsonXarelto$104$18,44713 claims
Lilly USA, LLCTrulicity$14$12,65915 claims
AbbVieLinzess, Synthroid$73$8,84949 claims
NovartisDiovan$13$8,09912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →